NCT06353061 is a Phase 2 clinical trial of Metformin in Cervical Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT06353061?

NCT06353061 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT06353061?

Interventions in NCT06353061: Metformin, Radiotherapy, Chemotherapy, PET/CT.

What condition does NCT06353061 study?

NCT06353061 studies Cervical Cancer, Radiotherapy, Metformin, Hypoxia, PET/CT.

Is NCT06353061 still recruiting?

NCT06353061 is currently recruiting now. Last updated 14 January 2025.

Last reviewed 2025-01-14 · How we verify

NCT06353061

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer

Recruiting now Phase 2 Last updated 14 January 2025

What this trial tests

Phase 2 trial testing Metformin in Cervical Cancer in 51 participants. Currently enrolling.

Timeline

15 April 2024

Primary endpoint
1 August 2025

1 February 2026

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	15 April 2024
Primary completion	1 August 2025
Estimated completion	1 February 2026
Sites	1 location across China

Drugs / interventions tested

Metformin (metformin) — full drug profile →
Radiotherapy — full drug profile →
Chemotherapy (chemotherapy) — full drug profile →
PET/CT

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →
Radiotherapy — all drugs for Radiotherapy →
Metformin — all drugs for Metformin →
Hypoxia — all drugs for Hypoxia →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 70, female only, with Cervical Cancer or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy.
Zhang H, Fan J, Kong D, Sun Y, et al · · 2025 · cited 8× · PMID 41063213 · DOI 10.1186/s12943-025-02460-1

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06353061 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 14 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06353061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing